Clinical trials: Covid19, Vaccines
COVID-19
Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.
This is a multicenter, randomized, observer blind clinical trial. A total of 750 evaluable HIV-infected (660) and HIV-uninfected (90) adult participants meeting all entry criteria (all inclusion and no exclusion criteria) will be…
- Trial name
- AUR1-8-341 (NCT05515042)
- Testing
- Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
- Where
- 5 sites in South Africa
- Volunteers
- 694 people, healthy volunteers welcome
- Sponsor
- The Aurum Institute NPC
Liver Cirrhosis
Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis
COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused widespread impact on health, including substantial mortality among those with pre-existing health conditions including…
- Trial name
- NCT04794946
- Testing
- Covishield
- Where
- India
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
COVID-19
Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina
The main of the study is to describe the incidence in health personnel who present events supposedly attributed to vaccines and immunizations after having received the two components of the Sputnik V vaccine, with the information…
- Trial name
- COVID-19 (NCT04738435)
- Where
- Argentina
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
SARS-CoV2 Infection
COVAXIN in a Pediatric Cohort
The study is designed to evaluate the safety, reactogenicity and immunogenicity of three groups ages ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years of healthy volunteers who receive two doses of the whole virion inactivated SARS-CoV-2 virus…
- Trial name
- COVAXIN-Peds (NCT04918797)
- Testing
- COVAXIN
- Where
- 7 sites in India
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects.
- Trial name
- NCT04776317
- Testing
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis
Medicine-induced Cardiac Hemodialysis on COVID-19
The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system.
- Conditions
- Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines, Myocarditis Allergic
- Trial name
- NCT05711810
- Testing
- Nifedipine 30 MG, Kangzhu BPCB0A-3A, Low Mobility
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Yang I. Pachankis
COVID-19 Vaccines, Hemodialysis Complication
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of…
- Trial name
- ROMANOV (NCT04881396)
- Testing
- Evaluation of the immunogenicity of the vaccine in haemodialysis patients
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma, Waldenstrom Macroglobulinemia
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
- Conditions
- Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
- Trial name
- NCT04830046
- Where
- 2 sites in United States
- Volunteers
- 146 people
- Sponsor
- Massachusetts General Hospital
COVID-19, Vaccine Hesitancy
Online Games to Help Canadian and U.S. Adults Identify COVID-19 and Vaccine Misinformation: Three Sequential Randomized Studies
COVID-19 misinformation contributed to vaccine hesitancy and preventable illness. This record covers three sequential randomized studies (conducted in Canada and the United States, November-December 2020) testing whether a brief…
- Conditions
- COVID-19, Vaccine Hesitancy, Health Misinformation, Communication
- Trial name
- NCT07758309
- Testing
- Gamified misinformation refutation quiz, Refutational text (active control)
- Where
- United States
- Volunteers
- 3,637 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Vaccine Hesitancy, Climate Change
Messaging Strategies to Increase Peer Education on COVID-19 Vaccination and Climate Change
The primary objective of this protocol is to develop and evaluate peer communication interventions to encourage peer education around COVID-19 vaccination and climate change.
- Trial name
- NCT05530044
- Testing
- Social diffusion intervention
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Covid-19, Vaccine
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
This is a prospective, single blinded randomized homologous/heterologous prime-boost vaccine clinical study, designed to assess the immunogenicity of heterologous prime-boost immunization with AZD1222 and MVC-COV1901 in adults.
- Conditions
- Covid-19, Vaccine, Immunogenicity, Reactogenicity
- Trial name
- NCT05054621
- Testing
- Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
COVID-19
Non-specific Effects of FLU-MMR Vaccines in Adults
Various observational studies have reported an association between influenza vaccination and lower rates of infection with SARS-Cov-2 and less COVID-19 disease severity have been reported in large epidemiological studies in US…
- Trial name
- FLUMMR-BRA (NCT05401448)
- Testing
- Influenza, MMR vaccines
- Where
- Brazil
- Volunteers
- 638 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
COVID-19, Vaccine Hesitancy
Testing a Personalized Normative Feedback Intervention for Vaccine Hesitancy
Rationale: The highest rates of coronavirus disease (i.e., COVID-19) vaccine hesitancy in the US are among young adults (YAs) aged 18-25.
- Trial name
- NCT05787015
- Testing
- Vaccine Norms Feedback, Alcohol Norms Feedback
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Washington
COVID-19, Rabies
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
- Trial name
- NCT05453487
- Testing
- coadministration, COVID-19 vaccine, rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
SARS-CoV-2 Infection, COVID19
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised.
- Trial name
- NCT04895982
- Testing
- BNT162b2
- Where
- 29 sites in United States, Brazil and 2 more
- Volunteers
- 124 people
- Sponsor
- BioNTech SE
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19 Vaccination, Vaccine Uptake
Supporting Audit and Feedback to Encourage Vaccine Uptake
In Ontario, approximately 6,000 family physicians can access a secure online system that provides a report that lists the COVID-19 vaccination status for each patient in their roster.
- Trial name
- NCT05099497
- Testing
- Using Practice Facilitators to Support Physicians
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
COVID-19, SARS CoV 2 Infection
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05372588)
- Testing
- NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515
- Where
- 19 sites in Australia
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV-2
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
- Trial name
- NCT04715997
- Testing
- GX-19N
- Where
- 5 sites in South Korea
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
COVID-19
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals
- Trial name
- PROFISCOV (NCT04456595)
- Testing
- Adsorbed COVID-19 (inactivated) Vaccine
- Where
- 16 sites in Brazil
- Volunteers
- 12,688 people, healthy volunteers welcome
- Sponsor
- Butantan Institute